Table 1 Comparison of baseline characteristics and angiographic findings
Controls(n = 24) | CSFP(n = 30) | OR [95% CI] | P-value | |
|---|---|---|---|---|
Demographics | ||||
Age (yrs) | 54.01 ± 8.14 | 56.31 ± 7.55 | 1.05 [0.99–1.12] | 0.09 |
Male sex [n(%)] | 12 (50%) | 20 (67%) | 2.00 [0.66–6.03] | 0.27 |
BMI (kg/m2) | 24.72 ± 3.46 | 24.13 ± 3.22 | 0.90 [0.78–1.10] | 0.34 |
Body surface area (m2) | 1.75 ± 0.15 | 1.73 ± 0.22 | 0.92 [0.80–1.12] | 0.78 |
Medical history | ||||
Smoking [n(%)] | 5 (21%) | 11 (37%) | 2.20 [0.64–7.56] | 0.24 |
Systolic blood pressure (mmHg) | 127.56 ± 14.26 | 125.33 ± 11.79 | 1.01 [0.98–1.05] | 0.39 |
Diastolic blood pressures (mmHg) | 76.89 ± 10.06 | 75.09 ± 8.90 | 1.02 [0.98–1.07] | 0.34 |
Hypertension [n(%)] | 11 (46%) | 10 (33%) | 0.59 [0.20–1.79] | 0.41 |
Diabetes mellitus [n(%)] | 3 (13%) | 2 (7%) | 0.50 [0.08–3.27] | 0.65 |
Duration of illness (months) | 12.0 (5.5–72.0) | 16.0 (7.0–48.0) | 1.00 [0.99–1.01] | 0.63 |
Laboratory values | ||||
Triglycerides (mmol/L) | 1.52 ± 1.00 | 1.49 ± 0.80 | 0.96 [0.56–1.67] | 0.90 |
Total cholesterol (mmol/L) | 4.43 ± 0.82 | 4.39 ± 0.76 | 0.93 [0.49–1.75] | 0.82 |
LDL cholesterol (mmol/L) | 2.69 ± 0.69 | 2.80 ± 0.65 | 1.28 [0.61–2.70] | 0.52 |
HDL cholesterol (mmol/L) | 1.25 ± 0.31 | 1.13 ± 0.32 | 0.26 [0.04–1.63] | 0.14 |
Fasting blood glucose (mmol/L) | 5.36 ± 0.73 | 5.54 ± 0.58 | 1.52 [0.70–3.27] | 0.29 |
Red blood cell count (1012/L) | 4.54 ± 0.37 | 4.60 ± 0.44 | 1.47 [0.41–5.21] | 0.56 |
Red cell distribution width (%) | 12.51 ± 0.55 | 12.91 ± 0.48 | 6.05 [1.52–24.03] | 0.004 |
Platelet count (109/L) | 211.24 ± 38.83 | 205.15 ± 41.13 | 0.99 [0.98–1.01] | 0.56 |
Platelet distribution width (%) | 12.04 ± 1.70 | 12.75 ± 1.55 | 1.31 [0.95–1.81] | 0.09 |
Total bilirubin (μmol/L) | 11.87 ± 4.54 | 10.67 ± 3.51 | 0.91 [0.82–1.09] | 0.12 |
Uric acid (μmol/L) | 292.76 ± 82.76 | 309.47 ± 64.96 | 1.01 [0.90–1.08] | 0.34 |
Fibrinogen (g/L) | 3.03 ± 0.61 | 2.88 ± 0.62 | 0.67 [0.29–1.53] | 0.34 |
Medications | ||||
Aspirin [n(%)] | 5 (21%) | 4 (13%) | 0.58 [0.14–2.47] | 0.49 |
ACEI/ARB [n(%)] | 7 (29%) | 14 (47%) | 2.13 [0.68–6.62] | 0.26 |
β-Blockers [n(%)] | 13 (54%) | 19 (63%) | 1.46 [0.49–4.36] | 0.58 |
Calcium channel blocker [n(%)] | 15 (63%) | 19 (63%) | 1.04 [0.34–3.15] | 0.99 |
Statin [n(%)] | 7 (29%) | 9 (30%) | 1.04 [0.32–3.38] | 0.99 |
Nitrates [n(%)] | 15 (63%) | 22 (73%) | 1.65 [0.52–5.25] | 0.56 |
Levocarnitine/Trimetazidine [n(%)] | 12 (50%) | 20 (67%) | 2.00 [0.66–6.03] | 0.27 |
TFC | ||||
cLAD | 23.08 ± 3.55 | 44.35 ± 15.41 | 1.41 [1.16–1.73] | < 0.001 |
LCX | 19.90 ± 3.90 | 33.74 ± 13.86 | 1.27 [1.11–1.44] | < 0.001 |
RCA | 22.52 ± 3.68 | 41.13 ± 15.50 | 1.59 [1.25–2.03] | < 0.001 |
Mean | 21.83 ± 2.54 | 39.74 ± 12.40 | 2.03 [1.35–3.06] | < 0.001 |